drugset
drugset / Trial / NCT03607513

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

NCT03607513 ↗

Phase 1 Completed 105 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The primary purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JNJ-64264681 in healthy participants after single and multiple oral doses.

Timeline

Start
2018-07-31
Primary completion
2019-08-09
Completion
2019-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64264681 Small molecule — Oral

Indications

No indication recorded.